A universal transduction enhancer specifically designed for hard-to-transduce primary human cells — T cells, NK cells, iPSCs — while retaining full compatibility with standard cell lines like HEK293T, CHO, HepG2, and HeLa.
High-Efficiency Transduction Enhancer
Cell type-optimized formulations for your research needs.
3-7× higher transduction efficiency vs. current standards in hard-to-transduce primary human cells.
1.3× better cell viability compared to current standards, preserving cell health and function.
Direct addition protocol in under 1 hour. Fits seamlessly into your existing transduction pipeline.
5-10× reduction in viral vector usage translates to significant manufacturing savings.
HiTE™ integrates seamlessly into standard transduction protocols — no special equipment, no workflow changes required.
Harvest and plate your target cells using your standard protocol. No pre-coating or special surface preparation needed.
Simply add HiTE™ peptide to your viral vector mix and apply to cells. Direct addition — no spinoculation required.
Standard incubation period. HiTE™ self-inactivates after 2 hours, preserving cell viability for downstream analysis.
Unlike traditional enhancers, HiTE™ peptides self-inactivate after facilitating viral entry — preserving cell health, differentiation potential, and downstream functionality. Validated with CAR, TCR, and reporter vectors (GFP, mCherry) across Primary T Cells, NK Cells, and iPSCs.
Head-to-head comparison across the metrics that matter most for cell therapy development.
| Parameter | HiTE™ | Current Standard | Plate Coating Methods |
|---|---|---|---|
| Transduction Efficiency | 3-7× higher | Baseline | Baseline |
| Cell Viability | 1.3× better | Baseline | Baseline |
| Workflow Time | <1 hour | <1 hour | >24 hours |
| Spinoculation Required | No | No | Often Required |
| Plate Coating Required | No | No | Yes |
| Vector Copy Number | <3 | >5 | >5 |
HiTE™ maintains vector copy numbers below the FDA guideline threshold of <5, supporting a clearer path to clinical translation.
Cell type-specific formulations engineered for the populations that matter most in cell therapy.
Ideal for CAR-T development. Works with activated, naive, and memory T cell subsets while preserving exhaustion profiles and proliferative capacity.
12.5× normalized fold change improvement. Compatible with primary NK cells and established cell lines for CAR-NK and adoptive transfer applications.
1.5× greater efficiency while preserving full differentiation potential for gene editing applications.
Validated with CAR, TCR large vectors and reporter vectors
(GFP, mCherry) across primary human cells.
Percentage of successfully transduced cells by enhancer type at low MOIs
Disclaimer: Performance data reflects internal testing under optimized conditions. Results may vary. See Terms of Service for details.
Technical documentation and protocols to support your research.
Join researchers worldwide achieving breakthrough results with HiTE™ technology. Our team is ready to support your development programs.